Results 81 to 90 of about 756,250 (282)

Aliskiren ยาใหม่ในกลุ่ม Renin Inhibitors

open access: yes, 2008
Aliskirenเป็นยาตัวแรกในกลุ่ม renin inhibitors ที่ได้รับการรับรองจากคณะกรรมการอาหารและยาประเทศสหรัฐอเมริกา เดือนมีนาคม ปี พ.ศ. 2550 ใช้สำหรับรักษาโรคความดันโลหิตสูงระดับอ่อนถึงปานกลาง โดยอาจใช้แบบเดี่ยว หรือใช้ร่วมกับยาลดความดันโลหิตสูงกลุ่มอื่น ๆ ...
ชนะกิจ, ธีราพร
core  

Einfluss des Cyclooxygenase-2-Inhibitors SC-236 auf ein stimuliertes wie unstimuliertes Renin-Angiotensin-Aldosteron-System [PDF]

open access: yes, 2022
Einfluss des Cyclooxygenase-2-Inhibitors SC-236 auf ein stimuliertes wie unstimuliertes Renin-Angiotensin-Aldosteron-System. Schwerpunkt dieser Arbeit ist die Frage in wie weit sich die Cyclooxygenase-2 auf die Stimulierbarkeit des Renin-Angiotensin-
Herrmann, Fabian
core  

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou   +3 more
wiley   +1 more source

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease

open access: yesActa Medica Indonesiana, 2020
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is a key strategy in treating hypertension in cardiovascular and renal diseases. However, RAAS inhibitors (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone ...
Yudi Her Oktaviono, Novia Kusumawardhani
doaj   +2 more sources

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction

open access: yesVascular Health and Risk Management, 2008
Paolo Verdecchia1, Fabio Angeli1, Giovanni Mazzotta1, Giorgio Gentile2, Gianpaolo Reboldi21Department of Cardiology, Clinical Research Unit ‘Preventive Cardiology’, Hospital ‘Santa Maria della Misericordia’, and Fondazione Umbra ...
Paolo Verdecchia   +4 more
doaj  

Renin inhibitors as possible antihypertensive agents

open access: yes, 1988
The blockade of the renin-angiotensin system by inhibition of angiotensin-converting enzyme has become an established principle in the treatment of hypertension.
Hofbauer, K. G., Wood, J. M.
core  

Hyponatremic hypertensive syndrome secondary to renal ischemia – Case report

open access: yesJournal of Pediatric and Neonatal Individualized Medicine, 2018
Hyponatremic hypertensive syndrome (HHS) is characterized by hypertensive crisis, and hyponatremia secondary to unilateral renal damage with glomerular and tubular dysfunction. Elevated plasma levels of renin in most cases suggest that the stimulation of
Joana Cunha Oliveira   +6 more
doaj   +1 more source

Donkwa Enriched With Goron‐Tula (Azanza garckeana) Modulates Sexual Behavior and Activity of Enzymes Linked With Erectile Dysfunction in High‐Fat Diets/ Streptozotocin‐Induced (STZ/HFD) Diabetic Rats

open access: yesFood Chemistry International, EarlyView.
(A) Mount number, (B) mount latency, (C) intromission number, and (D) intromission latency are the parameters of sexual behavior. Met = metformin. D100 = 100 Donkwa. D90G10 = 90% Donkwa + 10% Goron‐Tula. D85G15 = 85% Donkwa + 15% Goron‐Tula. D80G20 = 80% Donkwa + 20% Goron‐Tula. The mean ± standard error of the mean (SEM) expressed the results. *Values
O. T. Mamukuyomi   +2 more
wiley   +1 more source

Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors

open access: yes, 2008
Background The last decade has seen the introduction of renin inhibitors and new plasma renin and prorenin assays, which has led to a better understanding of the tissue renin - angiotensin system.
Deinum, J (Jacob)   +3 more
core   +2 more sources

Home - About - Disclaimer - Privacy